MA50858A - Procédés, compositions et composants pour l'édition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunothérapie - Google Patents

Procédés, compositions et composants pour l'édition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunothérapie

Info

Publication number
MA50858A
MA50858A MA050858A MA50858A MA50858A MA 50858 A MA50858 A MA 50858A MA 050858 A MA050858 A MA 050858A MA 50858 A MA50858 A MA 50858A MA 50858 A MA50858 A MA 50858A
Authority
MA
Morocco
Prior art keywords
tgfbr2
cas9
crispr
immunotherapy
edition
Prior art date
Application number
MA050858A
Other languages
English (en)
Inventor
Stephen Michael Burleigh
Melissa Chin
Fred Harbinski
Christopher Heath Nye
Blythe D Sather
Queenie Vong
Gordon Grant Welstead
Chris Wilson
Original Assignee
Editas Medicine Inc
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editas Medicine Inc, Juno Therapeutics Inc filed Critical Editas Medicine Inc
Publication of MA50858A publication Critical patent/MA50858A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
MA050858A 2017-11-01 2018-11-01 Procédés, compositions et composants pour l'édition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunothérapie MA50858A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762580320P 2017-11-01 2017-11-01

Publications (1)

Publication Number Publication Date
MA50858A true MA50858A (fr) 2020-09-09

Family

ID=64453598

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050858A MA50858A (fr) 2017-11-01 2018-11-01 Procédés, compositions et composants pour l'édition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunothérapie

Country Status (12)

Country Link
US (1) US20230061455A1 (fr)
EP (1) EP3704251A2 (fr)
JP (3) JP7785452B2 (fr)
CN (1) CN111527209B (fr)
AU (2) AU2018358250B2 (fr)
BR (1) BR112020008478A2 (fr)
CA (1) CA3081456A1 (fr)
IL (1) IL274299B1 (fr)
MA (1) MA50858A (fr)
MX (2) MX2020004608A (fr)
SG (1) SG11202003862PA (fr)
WO (1) WO2019089884A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
EP3773918A4 (fr) 2019-03-05 2022-01-05 Nkarta, Inc. Récepteurs d'antigènes chimériques anti-cd19 et leurs utilisations en immunothérapie
WO2020223535A1 (fr) * 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associés
BR112021021149A2 (pt) 2019-05-29 2021-12-14 Monsanto Technology Llc Métodos e composições para a geração de alelos dominantes utilizando a edição de genomas
MX2021014229A (es) 2019-05-29 2022-01-06 Monsanto Technology Llc Metodos y composiciones para generar alelos dominantes de baja estatura utilizando edicion genomica.
AU2020288829A1 (en) * 2019-06-04 2021-12-02 Nkarta, Inc. Combinations of engineered natural killer cells and engineered T cells for immunotherapy
WO2021011864A1 (fr) * 2019-07-18 2021-01-21 Memorial Sloan Kettering Cancer Center PROCÉDÉS ET COMPOSITIONS POUR CIBLER LA SIGNALISATION DU TGF-β DANS DES LYMPHOCYTES T AUXILIAIRES CD4+ POUR IMMUNOTHÉRAPIE ANTICANCÉREUSE
AU2020388690A1 (en) * 2019-11-20 2022-06-09 Cartherics Pty. Ltd. Method for providing immune cells with enhanced function
EP4076476A4 (fr) * 2019-12-17 2023-11-22 The General Hospital Corporation Cellules immunitaires modifiées à toxicité réduite et leurs utilisations
IL293946A (en) * 2019-12-18 2022-08-01 Editas Medicine Inc Engineered cells for therapy
KR20210116324A (ko) 2020-03-12 2021-09-27 기초과학연구원 게놈 서열 변이를 가지는 세포 사멸 유도용 조성물 및 상기 조성물을 이용한 세포 사멸 유도 방법
CN114164231B (zh) * 2020-09-10 2024-05-17 上海邦耀生物科技有限公司 对细胞中的靶位点进行基因编辑的方法
CN116322716A (zh) * 2020-09-23 2023-06-23 克里斯珀医疗股份公司 Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
US12171813B2 (en) 2021-02-05 2024-12-24 Christiana Care Gene Editing Institute, Inc. Methods of and compositions for reducing gene expression and/or activity
EP4326291A4 (fr) * 2021-04-20 2025-03-12 Board of Regents, The University of Texas System Procédés et compositions pour la modification génétique et l'utilisation thérapeutique de cellules immunitaires
WO2023081900A1 (fr) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Lymphocytes t modifiés exprimant un récepteur recombiné de lymphocytes t (tcr) et systèmes et procédés apparentés
JP2025504931A (ja) * 2022-01-26 2025-02-19 オーソバイオ・セラピューティクス，インコーポレイテッド 関節機能を改善する遺伝子編集
US20230331841A1 (en) * 2022-03-23 2023-10-19 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
WO2024058589A1 (fr) * 2022-09-16 2024-03-21 한국과학기술연구원 Cellule de récepteur antigénique chimérique préparée à l'aide d'une technique de knock-in par ciseaux génétiques et son utilisation
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
CN116515766A (zh) * 2023-06-30 2023-08-01 上海贝斯昂科生物科技有限公司 一种自然杀伤细胞、其制备方法及用途
WO2025038637A1 (fr) * 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions et procédés de modification génétique du récepteur bêta du facteur de croissance transformant de type 2 (tgfβr2)
IL326191A (en) * 2023-08-14 2026-03-01 Intellia Therapeutics Inc Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2)
WO2025137646A1 (fr) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Méthodes d'édition de gènes et compositions pour le traitement de la fibrose kystique
WO2025165915A1 (fr) * 2024-01-31 2025-08-07 Adicet Therapeutics, Inc. Compositions et procédés d'amélioration de thérapies par lymphocytes t modifiés
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (fr) 1994-10-26 1996-05-09 Procept, Inc. Recepteurs de lymphocites t monocatenaires solubles
WO1996018105A1 (fr) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Recepteur de lymphocyte t monocatenaire
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (fr) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
WO1999060120A2 (fr) 1998-05-19 1999-11-25 Avidex Limited Recepteur de lymphocyte t soluble
EP1109921A4 (fr) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2501870C (fr) 2002-10-09 2013-07-02 Avidex Limited Recepteurs de lymphocytes t de recombinaison a chaine unique
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
JP2008514685A (ja) 2004-10-01 2008-05-08 メディジーン リミテッド 治療剤に連結した、非天然型ジスルフィド鎖間結合を含有するｔ細胞レセプター
WO2008109546A2 (fr) * 2007-03-02 2008-09-12 Mdrna, Inc. Composés d'acide nucléique pour inhiber l'expression du gène tgfbr et utilisations de ceux-ci
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP2486049A1 (fr) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Récepteurs de lymphocytes t à chaîne unique humains
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
CA2861491C (fr) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Recepteurs d'antigene chimeres bispecifiques et utilisations therapeutiques de ceux-ci
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
EP2844743B1 (fr) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Récepteurs de lymphocyte t à affinité augmentée et procédés pour fabriquer ceux-ci
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN105247040A (zh) * 2012-10-05 2016-01-13 儿童医院医疗中心 皮脂细胞培养和使用方法
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
CN112301024A (zh) * 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
WO2014204723A1 (fr) * 2013-06-17 2014-12-24 The Broad Institute Inc. Modèles oncogènes basés sur la distribution et l'utilisation de systèmes crispr-cas, vecteurs et compositions
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
WO2015048577A2 (fr) * 2013-09-27 2015-04-02 Editas Medicine, Inc. Compositions et méthodes relatives aux répétitions palindromiques groupées, courtes et régulièrement espacées
CN106459995B (zh) * 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
ES2745769T3 (es) 2014-03-10 2020-03-03 Editas Medicine Inc Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
EP4464338A3 (fr) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systèmes pour améliorer l'édition génomique médiée par crispr/cas
EP3020813A1 (fr) * 2014-11-16 2016-05-18 Neurovision Pharma GmbH Oligonculéotides antisens en tant qu'inhibiteurs de la signalisation de TGF-R
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
EP3347026A4 (fr) * 2015-09-09 2019-05-08 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Modification génétique de macrophages pour l'immunothérapie

Also Published As

Publication number Publication date
US20230061455A1 (en) 2023-03-02
JP2025156493A (ja) 2025-10-14
AU2018358250B2 (en) 2025-06-05
KR20200075000A (ko) 2020-06-25
RU2020117752A (ru) 2021-12-01
CN111527209A (zh) 2020-08-11
CA3081456A1 (fr) 2019-05-09
JP7785452B2 (ja) 2025-12-15
JP2023179469A (ja) 2023-12-19
BR112020008478A2 (pt) 2020-10-20
AU2018358250A1 (en) 2020-05-14
IL274299B1 (en) 2026-01-01
MX2025010535A (es) 2025-10-01
IL274299A (en) 2020-06-30
CN111527209B (zh) 2024-11-12
SG11202003862PA (en) 2020-05-28
WO2019089884A2 (fr) 2019-05-09
AU2025223904A1 (en) 2025-09-18
WO2019089884A3 (fr) 2019-06-13
MX2020004608A (es) 2020-10-05
JP2021502113A (ja) 2021-01-28
EP3704251A2 (fr) 2020-09-09

Similar Documents

Publication Publication Date Title
MA50858A (fr) Procédés, compositions et composants pour l'édition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunothérapie
EP3370741A4 (fr) Procédés et compositions pour l'édition de gènes dans des cellules souches hématopoïétiques
MA47331A (fr) Compositions et procédés pour la déplétion des cellules cd137+
EP3472178A4 (fr) Compositions et procédés pour la déplétion des cellules cd117+
FR23C1015I1 (fr) Procédés de sélection d'une lignée de lymphocytes t et donneur de lignée de lymphocytes t pour thérapie cellulaire adoptive
EP3371301A4 (fr) Procédés et compositions pour induire la différenciation de cellules hématopoïétiques
EP3503901A4 (fr) Procédés et compositions pour cellules de moelle épinière
MA49981A (fr) Procédés et compositions de préparation de cellules génétiquement modifiées
EP3490366A4 (fr) Procédés et compositions pour l'expression de gènes dans des plantes
EP3429603A4 (fr) Procédés et compositions concernant l'expansion de cellules souches hématopoïétiques
EP3405568A4 (fr) Compositions et procédés de modulation des cellules immunitaires en immunothérapies adoptives
EP3717022A4 (fr) Compositions et procédés pour la déplétion des cellules cd5+
EP3886877A4 (fr) Procédés d'expansion simultanée de multiples types de cellules immunitaires, compositions associées et utilisations de celles-ci dans l'immunothérapie contre le cancer
MA43943A (fr) Compositions et procédés pour traiter des patients avec des cellules mutantes rtk
EP3307284A4 (fr) Compositions et procédés pour l'enrichissement de cellules
EP3635100A4 (fr) Compositions et procédés pour exprimer l'otoferline
MA49979A (fr) Procédés de production de compositions de cellules génétiquement modifiées et compositions associées
MA53445A (fr) Procédés et compositions pour la modification de plantes
EP3534911A4 (fr) Procédés et compositions pour la reprogrammation cellulaire
EP3645020A4 (fr) Compositions et procédés pour la thérapie cellulaire adoptive
EP3429609A4 (fr) Compositions et procédés pour le traitement de déficits en collagène de type vii
EP3645013A4 (fr) Compositions et procédés pour inhiber l'expression de hmgb1
EP3446123A4 (fr) Procédés et compositions pour pronostiquer une naissance prématurée
EP3684402A4 (fr) Compositions cellulaires comprenant des cellules t spécifiques de l'antigène pour thérapie adoptive
EP3347449A4 (fr) Procédés d'expansion de cellules et compositions thérapeutiques